Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 60Unknown 9Terminated 8Withdrawn 2Recruiting 1No longer available 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 71Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Leukemia, Biphenotypic, Acute 14Recurrence 13Myelodysplastic Syndromes 13Leukemia 12Burkitt Lymphoma 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myelomonocytic, Chronic 6Lymphoma, Mantle-Cell 5Neoplasm, Residual 4Myeloproliferative Disorders 4Lymphoma, Large B-Cell, Diffuse 4Hodgkin Disease 4Hematologic Neoplasms 4Sarcoma, Myeloid 3Lymphoma, T-Cell 3Lymphoma 3Blast Crisis 3Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myeloid 2Down Syndrome 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Anemia, Refractory, with Excess of Blasts 2Targeted Therapy 1Pyloric Stenosis, Hypertrophic 1Neurofibromatosis 1 1Neoplasms by Histologic Type 1

Interventions

fludarabine phosphate 1Injections 1Idarubicin 1Granulocyte Colony-Stimulating Factor 1Gemtuzumab 1Filgrastim 1Etoposide 1Decitabine 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Myelomonocytic, Acute × Cytarabine × Clear all
NCT00801489 2026-03-30

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 2 Recruiting
270 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡